Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL)

Exclusion Criteria

• •1. Has transvaginal and/or transabdominal ultrasound during the screening period demonstrating pathology other than uterine fibroids that could be responsible for or contributing to the patient's heavy menstrual bleeding, such as uterine or cervical polyps \> 2.0 cm, or any other clinically significant gynecological disorder determined by the investigator to require further evaluation and/or treatment.
• •Note: Saline or gel contrast is not routinely required. Use of such contrast is required only when the endometrium cannot be evaluated or when there are ambiguous and potentially exclusionary findings on the transvaginal and/or transabdominal ultrasound (e.g., suspected intrauterine masses, equivocal endometrial findings, etc.)
• •2. Has unexplained vaginal bleeding outside of the patient's regular menstrual cycle
• •3. Has undergone ultrasound-guided laparoscopic radiofrequency ablation, or any other surgical procedure for fibroids, uterine artery embolization, magnetic resonance-guided focused ultrasound for fibroids, as well as endometrial ablation for abnormal uterine bleeding within 6 months prior to the Screening visit
• •4. Has a history of or currently has osteoporosis, or other metabolic bone disease, hyperparathyroidism, hyperprolactinemia, hyperthyroidism, anorexia nervosa, or low traumatic (from the standing position) or atraumatic fracture (toe, finger, skull, face, and ankle fractures are allowed). A history of successfully treated hyperparathyroidism, hyperprolactinemia, or hyperthyroidism is allowed if the patient's bone mineral density is within normal limits
• •5. Has a history of the use of bisphosphonates, calcitonin, calcitriol, ipriflavone, teriparatide, denosumab, or any medication other than calcium and vitamin D preparations to treat bone mineral density loss
• •6. Anticipated use of systemic glucocorticoids at an oral prednisone-equivalent dose of more than 5 mg every other day during the study. Note: topical, inhaled, intranasal, optic, ophthalmic, intraarticular, or intralesional subcutaneous are permitted without restriction
• •7. Gastrointestinal disorder affecting absorption or gastrointestinal motility
• •8. Has any additional contraindication to treatment with low-dose estradiol and norethindrone acetate, including:
• •1. Current, known, suspected, or history of breast cancer
• •2. Current, known, or suspected hormone -dependent neoplasia
• •3. High risk of arterial, venous thrombotic disorder or thromboembolic disorder
• •i. women over 35 years of age who smoke or women with uncontrolled hypertension
• •d. Active thrombotic or thromboembolic disease or history of these conditions prior to the Baseline Day 1 visit or risk factors for such conditions. These conditions include: i. deep vein thrombosis ii. pulmonary embolism iii. vascular disease (e.g., cerebrovascular disease, coronary artery disease, peripheral vascular disease) iv. inherited or acquired hypercoagulopathies, known protein C, protein S, or antithrombin deficiency, or other known thrombophilia disorders, including Factor V Leiden thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) v. uncontrolled hypertension vi. headaches with focal neurological symptoms or migraine headaches with aura if over 35 years of age vii. Women at increased risks for thrombotic or thromboembolic events
• •e. Known anaphylactic reaction or angioedema or hypersensitivity to estradiol or norethindrone acetate
• •f. Currently pregnant or lactating, or intends to become pregnant or to donate ova during the study period or within 1 month after the end of the study
• •9. Has jaundice or known current active liver disease from any cause, including hepatitis A (HAV IgM), hepatitis B (HBsAg), or hepatitis C (HCV Ab positive, confirmed by HCV RNA);
• •10. Has any of the following cervical pathology: high grade cervical neoplasia, atypical glandular cells, atypical endocervical cells, atypical squamous cells favoring high grade. Of note, patients with atypical squamous cells of undetermined significance and low-grade cervical neoplasia may be included in the study if high risk human papilloma virus testing is negative or if DNA testing for human papilloma virus 16 and 18 DNA testing is negative
• •11. Has any of the following clinical laboratory abnormalities indicating hepatic or gallbladder impairment:
• •1. Alanine aminotransferase or aspartate aminotransferase \> 2.0 times the upper limit of normal (ULN), or bilirubin (total bilirubin) \> 1.5 x ULN on clinical laboratory testing at either the Screening 1 or Screening 2 visit (or \> 2.0 x ULN if secondary to Gilbert syndrome or pattern consistent with Gilbert syndrome);
• •2. Estimated glomerular filtration rate \< 60 mL/min/m2 using the Modification of Diet in Renal Disease method
• •12. Has clinically significant cardiovascular disease including:
• •1. Prior history of myocardial infarction
• •2. History of angina
• •3. History of congestive heart failure
• •4. History of clinically significant ventricular arrhythmias such as ventricular tachycardia, ventricular fibrillation, or torsade de pointes, or Mobitz II second degree or third-degree heart block without a permanent pacemaker in place or untreated supraventricular tachycardia (heart rate ≥ 120 beats per minute)
• •5. QT interval by the Fridericia correction formula (QTcF) of \> 470 msec
• •6. Hypotension, as indicated by systolic blood pressure \< 84 millimeters of mercury (mmHg) on 2 repeat measures at least 15 minutes apart or treated ongoing symptomatic orthostatic hypotension with \> 20 mmHg decrease in systolic blood pressure one minute or more after assuming an upright position.
• •7. Uncontrolled hypertension, as indicated by systolic blood pressure \> 160 mmHg on 2 repeat measures at least 15 minutes apart or diastolic blood pressure \> 100 mmHg at any screening visit or the Baseline Day 1 visit.
• •8. Bradycardia as indicated by a heart rate of \< 45 beats per minute on the screening electrocardiogram.
• •13. Has been a participant in an investigational drug or device study within the 1 month prior to Screening visit.
• •14. Has a history of clinically significant condition(s) including, but not limited to:
• •1. Untreated thyroid dysfunction or palpable thyroid abnormality (patients with adequately treated hypothyroidism who are stable on medication are not excluded).
• •2. History of malignancy within the past 5 years or ongoing malignancy other than curatively treated nonmelanoma skin cancer or surgically cured Stage 0 in situ melanoma
• •15. Any current psychiatric disorder that would, in the opinion of the investigator or medical monitor, impair the ability of the patient to participate in the study or would impair interpretation of their data. Patients with major depression, post-traumatic stress disorder, bipolar disorder, schizophrenia, or other psychotic disorders, based on Diagnostic and Statistical Manual of Mental Disorders-5 criteria who have been unstable based on the investigator's or mental health professional's judgement or whose psychiatric drug regimen has changed during the 3 months prior to Screening or is expected to change during the study should not be enrolled. Has a contraindication or history of sensitivity to any of the study treatments or components thereof; or has a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates study participation
• •16. Has a prior (within 1 year of Screening 1 visit) or current history of drug or alcohol abuse disorder according to Diagnostic and Statistical Manual of Mental Disorders V (all patients must be questioned about their drug and alcohol use, and this should be documented in the electronic case report form)
• •17. Has participated in a previous clinical study that included the use of Relugolix or has received this treatment within 3 months of the study.
• •18. Is inappropriate for participation in this study for other reasons, as determined by the investigator, sub-investigator, or medical monitor.